secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001493152-24-011615
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Daré Bioscience reports FY2023 net loss $30.1M, cash $10.5M; XACIATO launched, Ovaprene Phase 3 recruiting
--------------------------------------------------------------------------------

- Net loss of $30.1M for FY2023; revenue of $2.8M from XACIATO milestone payments.
- Cash and equivalents $10.5M at Dec 31, 2023; received $4.7M in grant funding and $17M in offerings/financing.
- XACIATO launched in U.S. via Organon; Daré eligible for double-digit royalties and up to $180M milestones.
- Ovaprene Phase 3 pivotal study recruiting at 17 U.S. sites; non-hormonal monthly contraceptive candidate.
- Sildenafil Cream completed Phase 2b; FDA feedback on Phase 3 design expected in Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000149315224011615/0001493152-24-011615-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000149315224011615/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-011615

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer